How social stress can worsen colitis, and what it reveals about the biology of IBD

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense stress are often followed by worsening symptoms or full-blown disease flares. Clinicians have observed the same phenomenon, yet the biological explanation has remained elusive—leaving stress dismissed by some as subjective, anecdotal or “all in the head.”

A new study is helping to change that narrative. Researchers from the University of Illinois have identified a biological pathway by which social stress can worsen colitis, linking psychological experience to measurable damage in the gut itself. Their findings show that stress activates β-adrenergic signaling in the intestine, triggering oxidative stress that weakens the gut lining and intensifies inflammation.

“Clinicians have long noticed that highly stressful events—death in the family, major life events, chronic life stress—often precede worsening symptoms and flares in patients with inflammatory bowel disease,” said one of the study’s authors, Jacob Allen, an associate professor in the Department of Health and Kinesiology in the College of Applied Health Sciences. “Our findings uncover potential physiological mechanisms for how stress can translate into changes in the gut that make IBD worse.”

Stress is known to activate the sympathetic nervous system—the body’s “fight-or-flight” response—leading to the release of catecholamines such as adrenaline and noradrenaline. These hormones prepare the heart, lungs and muscles for rapid action. What has been less clear is how they affect the gastrointestinal tract.

The researchers found that during social stress, these stress hormones rise not just in the bloodstream but locally within gut tissue itself. “What we found is that in response to social stress, these hormones are increased locally in the gut,” Allen said. “These stress signals can directly affect the gut lining … leading to increased production of reactive oxygen species (ROS), also known as free radicals.”

Reactive oxygen species are chemically reactive molecules that can damage cells if not tightly regulated. In this case, the study identified a specific ROS-producing pathway involving a protein called DUOX2. Excessive ROS weakened the intestinal epithelial barrier—the protective lining that keeps bacteria and toxins from leaking into underlying tissue—making the gut more inflamed and fragile.

“Overall, our data suggest that stress makes the gut environment more inflammatory and more fragile,” Allen said, adding that ROS signaling may be a “proximal trigger for why stress increases IBD flare risk.”

Importantly, the study suggests that stress does more than worsen existing inflammation. It may also prepare—or “prime”—the gut for future disease activity.

“Yes, stress clearly worsens ongoing inflammation,” said Elisa Caetano-Silva, a co-author of the study and a senior research scientist in Allen’s Integrative Microbiota & Physiology lab. “But interestingly, we also found evidence that stress-induced changes in the gut can precede active disease, priming the tissue to respond more strongly to later insults.”

This insight may help explain why patients sometimes experience flares weeks or months after stressful events, even if symptoms were initially absent. Stress, the researchers argue, can quietly reshape epithelial biology and redox signaling, increasing vulnerability long before inflammation becomes clinically obvious.

“In other words,” Caetano-Silva said, “stress can ‘set the stage’ for a flare by making the gut more vulnerable, even before symptoms appear.”

Rather than using physical stressors such as pain or restraint, the researchers focused on social stress—an experimental model that mimics psychological stressors relevant to human experience.

“We chose social stress because it strongly activates adrenergic signaling … which is very relevant to certain types of human psychological stress,” Allen said, including conditions such as post-traumatic stress disorder.

Stress is often framed primarily as a cortisol problem, linked to the hypothalamic-pituitary-adrenal, or HPA, axis. But in this study, blocking cortisol signaling did not prevent stress-induced worsening of colitis. Blocking β-adrenergic signaling, however, did.

“In this model and in this context, adrenergic signaling appears to be the dominant driver of stress-induced worsening of gut inflammation,” Allen said, while emphasizing that cortisol is not irrelevant in all settings.

One of the most striking findings was that inhibiting oxidative stress itself could blunt the harmful effects of stress. A compound called apocynin, which limits ROS production, significantly reduced stress-related disease severity in mice.

“We were especially excited by how well a ROS-targeting compound worked in limiting stress-induced worsening of IBD,” Allen said. “Whether this translates to humans is a critical next question … but it’s promising.”

The work also raises—but does not answer—questions about existing drugs. Because β-adrenergic signaling was central to disease worsening, could medications like β-blockers play a role in IBD care?

“Potentially … but we need to be careful,” Allen cautioned. “It’s too early to recommend β-blockers for IBD management” without controlled human studies examining safety, timing, and patient subgroups.

Allen and Caetano-Silva were equally clear about what patients should not take away. “I would caution patients not to interpret this as: ‘Just take a beta-blocker and your IBD will improve,’” Allen said. “IBD is complex, and it’s unlikely that one intervention will solve everything.”

The study also challenges how medicine talks about stress itself. Too often, stress is framed as a personal failing or a psychological weakness. This research pushes back against that framing.

“It supports the idea that stress isn’t ‘just in your head,’” Allen said. “It can create measurable biological changes that affect gut physiology and immune responses.”

By identifying specific pathways—adrenergic signaling, epithelial oxidative stress and barrier dysfunction—the work reframes stress as a biological factor that can be studied, measured, and potentially treated.

Looking ahead, the researchers envision a more integrated future for IBD care. “I don’t think IBD will ever be treated by one drug,” Allen said. “But the future is more holistic and personalized care—combining immune-targeting therapies, strategies to strengthen gut barrier function, microbiome-targeted interventions and approaches that reduce stress-driven inflammation.”

If that future arrives, patients’ long-standing intuition—that stress matters—may finally be matched by equally strong biological evidence.

Related news